Inhibition of hypoxia inducible factor by phenethyl isothiocyanate

Biochemical Pharmacology

Volumn 78, Issue 3, 2009, Pages 261-272

  Wang, Xiu Hong ^a   Cavell, Breeze E ^a   Syed Alwi, Sharifah S ^a   Packham, Graham ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Angiogenesis; Degradation; Hypoxia inducible factor; Phenethyl isothiocyanate; Translation

Indexed keywords

COBALT CHLORIDE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHENETHYL ISOTHIOCYANATE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEASOME; RNA; VON HIPPEL LINDAU PROTEIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA TRANSLATION; TRANSLATION REGULATION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOTHIOCYANATES; PHOSPHORYLATION; PROCOLLAGEN-PROLINE DIOXYGENASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 65749104457     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.04.010     Document Type: Article

References (80)

1. Dashwood R.H., and Ho E. Dietary agents as histone deacetylase inhibitors: sulforaphane and structurally related isothiocyanates. Nutr Rev 66 Suppl. 1 (2008) S36-S38
2. Keum Y.S., Jeong W.S., and Kong A.N. Chemopreventive functions of isothiocyanates. Drug News Perspect 18 (2005) 445-451
3. Conaway C.C., Yang Y.M., and Chung F.L. Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. Curr Drug Metab 3 (2002) 233-255
4. Higdon J.V., Delage B., Williams D.E., and Dashwood R.H. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 55 (2007) 224-236
5. Zhang Y., Kensler T.W., Cho C.G., Posner G.H., and Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci U S A 91 (1994) 3147-3150
6. Zhang Y., and Talalay P. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res 54 (1994) 1976s-1981s
7. Hecht S.S. Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev 32 (2000) 395-411
8. Kwak M.K., Itoh K., Yamamoto M., Sutter T.R., and Kensler T.W. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1,2-dimethiole-3-thione. Mol Med 7 (2001) 135-145
9. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236 (1997) 313-322
10. Motohashi H., and Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 10 (2004) 549-557
11. Kobayashi A., Kang M.I., Okawa H., Ohtsuji M., Zenke Y., Chiba T., et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24 (2004) 7130-7139
12. Kobayashi A., Kang M.I., Watai Y., Tong K.I., Shibata T., Uchida K., et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol 26 (2006) 221-229
13. Zhang D.D., Lo S.C., Cross J.V., Templeton D.J., and Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24 (2004) 10941-10953
14. Dinkova-Kostova A.T., Holtzclaw W.D., Cole R.N., Itoh K., Wakabayashi N., Katoh Y., et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A 99 (2002) 11908-11913
15. Keum Y.S., Owuor E.D., Kim B.R., Hu R., and Kong A.N. Involvement of Nrf2 and JNK1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent phenethyl isothiocyanate (PEITC). Pharm Res 20 (2003) 1351-1356
16. McMahon M., Itoh K., Yamamoto M., and Hayes J.D. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 278 (2003) 21592-21600
17. Xu C., Yuan X., Pan Z., Shen G., Kim J.H., Yu S., et al. Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. Mol Cancer Ther 5 (2006) 1918-1926
18. Zhang D.D., and Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 23 (2003) 8137-8151
19. Fahey J.W., Haristoy X., Dolan P.M., Kensler T.W., Scholtus I., Stephenson K.K., et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A 99 (2002) 7610-7615
20. Zhang Y., Yao S., and Li J. Vegetable-derived isothiocyanates: anti-proliferative activity and mechanism of action. Proc Nutr Soc 65 (2006) 68-75
21. Myzak M.C., and Dashwood R.H. Chemoprotection by sulforaphane: keep one eye beyond Keap1. Cancer Lett 233 (2006) 208-218
22. Pham N.A., Jacobberger J.W., Schimmer A.D., Cao P., Gronda M., and Hedley D.W. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther 3 (2004) 1239-1248
23. Xiao D., Johnson C.S., Trump D.L., and Singh S.V. Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther 3 (2004) 567-575
24. Trachootham D., Zhang H., Zhang W., Feng L., Du M., Zhou Y., et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 112 (2008) 1912-1922
25. Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10 (2006) 241-252
26. Myzak M.C., Dashwood W.M., Orner G.A., Ho E., and Dashwood R.H. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J 20 (2006) 506-508
27. Myzak M.C., Tong P., Dashwood W.M., Dashwood R.H., and Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) 232 (2007) 227-234
28. Srivastava S.K., Xiao D., Lew K.L., Hershberger P., Kokkinakis D.M., Johnson C.S., et al. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo. Carcinogenesis 24 (2003) 1665-1670
29. Xiao D., Lew K.L., Zeng Y., Xiao H., Marynowski S.W., Dhir R., et al. Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis 27 (2006) 2223-2234
30. Zhang Y. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. Carcinogenesis 21 (2000) 1175-1182
31. Xu K., and Thornalley P.J. Involvement of glutathione metabolism in the cytotoxicity of the phenethyl isothiocyanate and its cysteine conjugate to human leukaemia cells in vitro. Biochem Pharmacol 61 (2001) 165-177
32. Mi L., Wang X., Govind S., Hood B.L., Veenstra T.D., Conrads T.P., et al. The role of protein binding in induction of apoptosis by phenethyl isothiocyanate and sulforaphane in human non-small lung cancer cells. Cancer Res 67 (2007) 6409-6416
33. Mi L., Xiao Z., Hood B.L., Dakshanamurthy S., Wang X., Govind S., et al. Covalent binding to tubulin by isothiocyanates. A mechanism of cell growth arrest and apoptosis. J Biol Chem 283 (2008) 22136-22146
34. Heiss E., Herhaus C., Klimo K., Bartsch H., and Gerhauser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 276 (2001) 32008-32015
35. Zhu M., Zhang Y., Cooper S., Sikorski E., Rohwer J., and Bowden G.T. Phase II enzyme inducer, sulforaphane, inhibits UVB-induced AP-1 activation in human keratinocytes by a novel mechanism. Mol Carcinog 41 (2004) 179-186
36. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
37. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
38. Rankin E.B., and Giaccia A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15 (2008) 678-685
39. Weidemann A., and Johnson R.S. Biology of HIF-1alpha. Cell Death Differ 15 (2008) 621-627
40. Pouyssegur J., and Mechta-Grigoriou F. Redox regulation of the hypoxia-inducible factor. Biol Chem 387 (2006) 1337-1346
41. 2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 271 (1996) 21793-21797
42. Gao N., Ding M., Zheng J.Z., Zhang Z., Leonard S.S., Liu K.J., et al. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem 277 (2002) 31963-31971
43. Gorlach A., Diebold I., Schini-Kerth V.B., Berchner-Pfannschmidt U., Roth U., Brandes R.P., et al. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: role of the p22(phox)-containing NADPH oxidase. Circ Res 89 (2001) 47-54
44. Park J.H., Kim T.Y., Jong H.S., Chun Y.S., Park J.W., Lee C.T., et al. Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells. Clin Cancer Res 9 (2003) 433-440
45. Shatrov V.A., Sumbayev V.V., Zhou J., and Brune B. Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1alpha (HIF-1alpha) accumulation via redox-dependent mechanisms. Blood 101 (2003) 4847-4849
46. Tacchini L., Dansi P., Matteucci E., and Desiderio M.A. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 22 (2001) 1363-1371
47. Guzy R.D., Hoyos B., Robin E., Chen H., Liu L., Mansfield K.D., et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1 (2005) 401-408
48. Brunelle J.K., Bell E.L., Quesada N.M., Vercauteren K., Tiranti V., Zeviani M., et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 1 (2005) 409-414
49. Mansfield K.D., Guzy R.D., Pan Y., Young R.M., Cash T.P., Schumacker P.T., et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab 1 (2005) 393-399
50. Hirota K., and Semenza G.L. Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem 276 (2001) 21166-21172
51. 2 sensing. J Biol Chem 275 (2000) 25130-25138
52. Xiao D., and Singh S.V. Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. Cancer Res 67 (2007) 2239-2246
53. Bertl E., Bartsch H., and Gerhauser C. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol Cancer Ther 5 (2006) 575-585
54. Jackson S.J., Singletary K.W., and Venema R.C. Sulforaphane suppresses angiogenesis and disrupts endothelial mitotic progression and microtubule polymerization. Vascul Pharmacol 46 (2007) 77-84
55. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62 (2002) 4316-4324
56. Brimmell M., Burns J.S., Munson P., McDonald L., O'Hare M.J., Lakhani S.R., et al. High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers. Br J Cancer 81 (1999) 1042-1051
57. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., and Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392 (1998) 405-408
58. Shoshani T., Faerman A., Mett I., Zelin E., Tenne T., Gorodin S., et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 22 (2002) 2283-2293
59. Tseng E., Scott-Ramsay E.A., and Morris M.E. Dietary organic isothiocyanates are cytotoxic in human breast cancer MCF-7 and mammary epithelial MCF-12A cell lines. Exp Biol Med (Maywood) 229 (2004) 835-842
60. Lee J.W., and Cho M.K. Phenethyl isothiocyanate induced apoptosis via down regulation of Bcl-2/XIAP and triggering of the mitochondrial pathway in MCF-7 cells. Arch Pharm Res 31 (2008) 1604-1612
61. Ke Q., and Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70 (2006) 1469-1480
62. Lofstedt T., Fredlund E., Holmquist-Mengelbier L., Pietras A., Ovenberger M., Poellinger L., et al. Hypoxia inducible factor-2alpha in cancer. Cell Cycle 6 (2007) 919-926
63. Appelhoff R.J., Tian Y.M., Raval R.R., Turley H., Harris A.L., Pugh C.W., et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279 (2004) 38458-38465
64. Krieg M., Haas R., Brauch H., Acker T., Flamme I., and Plate K.H. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19 (2000) 5435-5443
65. Uchida T., Rossignol F., Matthay M.A., Mounier R., Couette S., Clottes E., et al. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J Biol Chem 279 (2004) 14871-14878
66. Holmquist-Mengelbier L., Fredlund E., Lofstedt T., Noguera R., Navarro S., Nilsson H., et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10 (2006) 413-423
67. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
68. Zhang H., Trachootham D., Lu W., Carew J., Giles F.J., Keating M.J., et al. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 22 (2008) 1191-1199
69. Yee Koh M., Spivak-Kroizman T.R., and Powis G. HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci 33 (2008) 526-534
70. Hu J., Straub J., Xiao D., Singh S.V., Yang H.S., Sonenberg N., et al. Phenethyl isothiocyanate, a cancer chemopreventive constituent of cruciferous vegetables, inhibits cap-dependent translation by regulating the level and phosphorylation of 4E-BP1. Cancer Res 67 (2007) 3569-3573
71. Yao H., Wang H., Zhang Z., Jiang B.H., Luo J., and Shi X. Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. Int J Cancer 123 (2008) 1255-1261
72. Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K., et al. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18 (1999) 1905-1914
73. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25 (2005) 5675-5686
74. Carroll V.A., and Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66 (2006) 6264-6270
75. Sowter H.M., Raval R.R., Moore J.W., Ratcliffe P.J., and Harris A.L. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 63 (2003) 6130-6134
76. Gordan J.D., Lal P., Dondeti V.R., Letrero R., Parekh K.N., Oquendo C.E., et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14 (2008) 435-446
77. Averous J., and Proud C.G. When translation meets transformation: the mTOR story. Oncogene 25 (2006) 6423-6435
78. Dames S.A., Mulet J.M., Rathgeb-Szabo K., Hall M.N., and Grzesiek S. The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability. J Biol Chem 280 (2005) 20558-20564
79. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122-127
80. Bhatt R.S., Landis D.M., Zimmer M., Torregrossa J., Chen S., Sukhatme V.P., et al. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int 102 (2008) 358-363